GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Cash Ratio

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Cash Ratio : 1.29 (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Aerie Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2022 was 1.29.

Aerie Pharmaceuticals has a Cash Ratio of 1.29. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Aerie Pharmaceuticals's Cash Ratio or its related term are showing as below:

AERI' s Cash Ratio Range Over the Past 10 Years
Min: 0.2   Med: 6.15   Max: 24.44
Current: 1.29

During the past 11 years, Aerie Pharmaceuticals's highest Cash Ratio was 24.44. The lowest was 0.20. And the median was 6.15.

AERI's Cash Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.57 vs AERI: 1.29

Aerie Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Aerie Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Cash Ratio Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.91 3.99 3.70 2.30 1.12

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 1.12 1.69 1.54 1.29

Competitive Comparison of Aerie Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Cash Ratio falls into.



Aerie Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Aerie Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash Ratio (A: Dec. 2021 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=139.801/124.991
=1.12

Aerie Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash Ratio (Q: Sep. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=172.464/133.333
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerie Pharmaceuticals  (NAS:AERI) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Aerie Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines

From GuruFocus

RICE HALL JAMES & ASSOCIATES, LLC Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-27-2023

Top 5 4th Quarter Trades of PINNACLE ASSOCIATES LTD

By GuruFocus Research GuruFocus Editor 01-25-2023

Aerie Pharmaceuticals Announces New Employee Inducement Grant

By Business Wire Business Wire 07-08-2022

LEVIN CAPITAL STRATEGIES, L.P. Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023